Description

Acute Conjunctivitis Treatment Market report gives a comprehensive outlook on global market scenario, growth trends, shares, with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The report on the global Acute Conjunctivitis Treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of type, dosage form, drug class, distribution channel and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyze the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include manufacturers, distributors, policy makers, and service providers engaged in Acute Conjunctivitis Treatment.

Conjunctivitis, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Conjunctivitis can be highly communicable and can be spread easily by contact with secretions of eye from the infected person. Symptoms includes tearing, itching and redness of the eyes. It can also lead to discharge or crusting around the eyes. It’s important to stop wearing contact lenses whilst affected by conjunctivitis. Conjunctivitis often resolves on its own, but treatment can speed up the recovery process. Allergic conjunctivitis can be treated with antihistamines. Bacterial conjunctivitis can be treated with antibiotic eye drops.In June 2017, Teva Pharmaceuticals launched, generic version of Pataday (olopatadine hydrochloride ophthalmic solution) 0.2%, in U.S used to treat Allergic conjunctivitis In February 2015, Novartis division, Alcon has received USFDA approval for Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7%, to treat ocular itching which is associated with allergic conjunctivitis.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX